Assessment and Management of Clostridioides difficile Infections (CDI)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.

**PRESENTATION**

Patient with 3 unformed stools in last 24 hours

**ASSESSMENT**

Stop laxative (if applicable) and reassess in 24 hours for clinical response prior to ordering Clostridioides difficile testing

Has patient taken laxatives over the past 24-48 hours?

- Yes
  - Seek alternate explanation for diarrhea
- No
  - Has C. difficile DNA assay been ordered less than 7 days prior?
    - Yes
      - Enter order for a single stool specimen for C. difficile DNA assay
    - No
      - C. difficile DNA assay positive?
        - Yes
          - Continue contact isolation
        - No
          - Have signs/symptoms resolved for 24 hours or are there alternative non-infectious causes of diarrheal symptoms identified?

**INTERVENTION**

- For initial episode, severe and fulminant disease criteria and treatment, see Pages 2-3
- For initial episode, non-severe disease criteria and treatment, see Page 4
- For recurrent disease criteria and treatment, see Page 5
- Colonization is likely. Treatment usually not indicated; use clinical judgement in determining need for treatment.
- Contact Infection Control to remove isolation precautions

ELISA = enzyme-linked immunosorbent assay

1. Consider CDI when faced with unexplained ileus
2. Consider other therapies/treatments that contribute to diarrhea before ordering test for C. difficile, such as tube feeding, chemotherapy and oral contrast
3. Given the high sensitivity (greater than 95%) for the DNA assay test, a single stool specimen is sufficient; repeated testing over three days is no longer necessary
4. See Appendix A for Bristol Chart
5. Reflective ELISA for C. difficile toxins A and B will be performed on all positive DNA assays. Use clinical judgement in interpreting significance of DNA positive, ELISA negative results.
6. Do not retest within 7 days, regardless of result
7. Infection Control (IC): Phone: (713) 792-3655 | Email: INFECTIONCONTROL@mdanderson.org

Copyright 2019 The University of Texas MD Anderson Cancer Center

Approved by the Executive Committee of the Medical Staff on 09/17/2019
**Initial episode, severe disease**
- Presence of visualized pseudomembranes on endoscopy, able to take oral medications and/or
- Any two of the following:
  - Adult patients age greater than 60 years
  - WBC greater than 15 K/microliter or ANC less than 0.5 K/microliter
  - Serum creatinine (Scr)
    - Adults: greater than 1.5 mg/dL
    - Children: less than 2 years, Scr greater than 0.5 mg/dL; 2-8 years, Scr greater than 0.7 mg/dL; 9-18 years, Scr greater than 0.9 mg/dL
  - Albumin less than 2.5 g/dL
  - GI graft versus host disease (GVHD)
  - Fever greater than 38.3°C
  - Abdominal cramping/pain
  - CT finding with colonic thickening, ascites, or pneumatosis
  - Greater than 10 episodes of diarrhea per day
  - Concomitant chemotherapy or immunosuppression (including corticosteroids)

For patients who do not meet criteria for **severe** or **fulminant disease**, see **Page 4** for **non-severe disease** treatment

---

1. Refer to Appendix B for supportive care considerations
2. May substitute with capsules if oral solution not available
3. Concomitant antibiotic therapy for another infection is no longer needed
4. Concomitant antibiotic therapy for another infection is needed
5. Refer to Appendix C for institutional use criteria
DISEASE SEVERITY

Initial episode, fulminant disease
- Presence of any of the following:
  - Admission to the ICU
  - Septic shock
  - Toxic megacolon
  - Peritonitis
  - Ileus
  - Perforation
  - Unable to take oral medications

TREATMENT

Adult:
- Metronidazole 500 mg IV every 8 hours
  - Vancomycin 500 mg oral solution PO or via NGT every 6 hours or
  - Fidaxomicin 200 mg PO or via NGT every 12 hours
- Consider use of vancomycin retention enema [500 mg in 100 mL normal saline (NS) per rectum every 6 hours] if patient not neutropenic

Pediatric:
- Metronidazole 30 mg/kg/day IV divided every 8 hours (maximum dose of 2 g/day) and
- Vancomycin 40 mg/kg/day oral solution PO divided every 6 hours (maximum dose of 2 g/day)
- Consider use of vancomycin retention enema dosed every 6 hours if patient not neutropenic
  - 1-3 years: 250 mg in 50 mL NS
  - 4-9 years: 375 mg in 75 mL NS
  - Greater than and equal to 10 years: 500 mg in 100 mL NS

All patients:
- Consider Surgery, Infectious Diseases, and Gastroenterology consultation(s)

REASSESSMENT

- Continue treatment for 10-14 days of therapy
- Reassess appropriateness of therapy continuously based on the patient’s clinical status
- Obtain Infectious Diseases and Gastroenterology consultations for possible fecal microbiota transplant (FMT)

For patients who do not meet criteria for severe or fulminant disease, see Page 4 for non-severe disease treatment

1 Refer to Appendix B for supportive care considerations
2 May substitute with capsules if oral solution not available
3 Refer to Appendix D for fecal microbiota transplant indications

Assessment and Management of Clostridioides difficile Infections (CDI)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.
Assessment and Management of Clostridioides difficile Infections (CDI)

Initial disease, non-severe
- Does not meet criteria for severe or fulminant disease

**DISEASE SEVERITY**

**TREATMENT**

**Adult:**
- **First line**
  - Vancomycin 125 mg oral solution\(^2\) PO every 6 hours for 10 days or
  - Fidaxomicin 200 mg PO twice daily for 10 days

**Second line** (if above agents are not available)
- Metronidazole\(^3\) 500 mg PO every 8 hours for 10 days

**Pediatric:**
- **First line**
  - Metronidazole 30 mg/kg/day PO divided every 6 hours for 10-14 days
  - Vancomycin 40 mg/kg/day oral solution\(^3\) PO divided every 6 hours for 10-14 days (maximum dose of 500 mg/day)

**Note:** Carefully review concomitant antimicrobials and stop any that are not absolutely necessary

\(^1\) Refer to Appendix B for supportive care considerations

\(^2\) May substitute with capsules if oral solution not available

\(^3\) Avoid concomitant use of busulfan due to higher risk of sinusoidal obstruction syndrome (SOS)

\(^4\) Refer to Appendix C for institutional use criteria

**INTERVENTION**

- Complete course of therapy
- For adult patients, use bezlotoxumab\(^4\) if institutional criteria met

Reassess symptoms after 3 days

Yes → Improvement?
- Obtain Infectious Diseases consultation
- Treatment failures at three days should be transitioned to vancomycin (if previously on metronidazole) or fidaxomicin

No → Improvement?
- Treatment failures at three days should be transitioned to vancomycin (if previously on metronidazole) or fidaxomicin

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.
TREATMENT

Recurrence

Diarrhea due to CDI (patient must have completed 10-14 days of effective therapy and have no symptoms for 48 hours after treatment has ended)

Adult:
- Vancomycin 125 mg oral solution^3 PO every 6 hours for 10 days if metronidazole was used for the first episode \textbf{or}
- Fidaxomicin 200 mg PO twice daily for 10 days if vancomycin was used for the first episode \textbf{or}
- Vancomycin tapering/pulse treatment if vancomycin or fidaxomicin was used for the first episode:
  - 125 mg oral solution PO every 6 hours for 14 days, then every 12 hours for 14 days, then once daily for 7 days, then every other day for 4 doses, then every third day for 5 doses, then off
  - Some patients may require chronic suppression thereafter
- For all regimens, use bezlotoxumab\(^4\) if institutional criteria are met and not previously administered

Pediatric: See Page 6

First recurrence

Second and subsequent recurrences

See Page 7

\(^1\) Clindamycin and fluoroquinolones are associated with the highest risk of CDI. Whenever possible, avoid these agents and all other unnecessary antibiotics, particularly those with anaerobic activity such as ampicillin/sulbactam, piperacillin/tazo/bactam, and carbapenems.
\(^2\) Refer to Appendix E for prevention considerations.
\(^3\) May substitute with capsules if oral solution not available.
\(^4\) Refer to Appendix C for institutional use criteria.

\(^5\) Refer to Appendix D for fecal microbiota transplant indications.
\(^6\) Refer to Infectious Disease Clinic at (713) 792-2340 or Gastroenterology at (713) 794-5073.

Consider fecal microbiota transplant (FMT)\(^5,6\) if first two episodes were associated with hospitalization or significant morbidity.

Consider Infectious Diseases and Gastroenterology consultations for additional work up and possible FMT\(^5,6\).

Reassess symptoms after 3 days

Improvement?

Yes

No

Note: Avoid use of unnecessary antibiotics\(^1\)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.
Clindamycin and fluoroquinolones are associated with the highest risk of CDI. Whenever possible, avoid these agents and all other unnecessary antibiotics, particularly those with anaerobic activity such as ampicillin/sulbactam, piperacillin/tazobactam, and carbapenems.

May substitute with capsules if oral solution not available.

Fidaxomicin is not FDA approved in patients less than 18 years of age but there is phase IIa data to support use in recurrent disease.

Assessment and Management of Clostridioides difficile Infections (CDI)

RECURRENT

TREATMENT

First recurrence

Pediatric:

- Vancomycin 40 mg/kg/day oral solution if metronidazole was used for the first episode or
- Fidaxomicin if vancomycin was used for the first episode
  - Age 6 years to less than 18 years: 200 mg tablets PO twice daily for 10 days or
  - Vancomycin tapering/pulse treatment (for children under 18 years) if vancomycin or fidaxomicin was used for the first episode:
    - 10 mg/kg/dose oral solution PO every 6 hours for 14 days, then every 12 hours for 14 days, then once daily for 7 days, then every other day for 4 doses, then every third day for 5 doses, then off

Improvement?

Reassess symptoms after 3 days

Yes

Consider fecal microbiota transplant (FMT) if first two episodes were associated with hospitalization or significant morbidity

No

Consider Infectious Diseases and Gastroenterology consultations for additional work up and possible FMT

Second and subsequent recurrences

See Page 7

1 Clindamycin and fluoroquinolones are associated with the highest risk of CDI. Whenever possible, avoid these agents and all other unnecessary antibiotics, particularly those with anaerobic activity such as ampicillin/sulbactam, piperacillin/tazobactam, and carbapenems.

2 Refer to Appendix E for prevention considerations

3 May substitute with capsules if oral solution not available

Fidaxomicin is not FDA approved in patients less than 18 years of age but there is phase IIa data to support use in recurrent disease

5 Refer to Appendix D for fecal microbiota transplant indications

6 Refer to Infectious Disease Clinic at (713) 792-2340 or Gastroenterology at (713) 794-5073
TREATMENT

RECURRENT

Adult:
- Vancomycin followed by tapering/pulse treatment:
  - 125 mg oral solution PO every 6 hours for 14 days, then every 12 hours for 14 days, then once daily for 7 days, then every other day for 4 doses, then every third day for 5 doses, then off
  - Some patients may require chronic suppression thereafter

  or

- Fidaxomicin 200 mg PO twice daily for 10 days
- Consider Infectious Diseases consultation
- For all regimens, use bezlotoxumab if institutional criteria met and not previously administered. If previously administered, consider use on case-by-case basis.
- Consider FMT

Pediatric:
- Fidaxomicin if vancomycin was used for the first episode
  - Age 6 years to less than 18 years: 200 mg tablets PO twice daily for 10 days or Vancomycin tapering/pulse treatment (for children under 18 years) if vancomycin or fidaxomicin was used for the first episode:
    - 10 mg/kg/dose oral solution PO every 6 hours for 14 days, then every 12 hours for 14 days, then once daily for 7 days, then every other day for 4 doses, then every third day for 5 doses, then off
  - Some patients may require chronic suppression thereafter

Second and subsequent recurrences

Reassess symptoms after 3 days

Yes

Monitor recurrence

Improvement?

No

- Consider alternate causes such as post-infectious diarrhea
- Consider FMT

1 Clindamycin and fluoroquinolones are associated with the highest risk of CDI. Whenever possible, avoid these agents and all other unnecessary antibiotics, particularly those with anaerobic activity such as ampicillin/sulbactam, piperacillin/tazobactam, and carbapenems.
2 Refer to Appendix E for prevention considerations
3 May substitute with capsules if oral solution not available
4 Fidaxomicin is not FDA approved in patients less than 18 years of age but there is phase IIa data to support use in recurrent disease
5 Refer to Appendix C for institutional use criteria
6 Refer to Appendix D for fecal microbiota transplant indications
7 Refer to Infectious Disease Clinic at (713) 792-2340 or Pediatric Infectious Disease at (713) 792-6610 or Gastroenterology at (713) 794-5073
8 Consider continuing prophylaxis in selected patients and those awaiting FMT (consult Gastroenterology and Infectious Diseases)

Note: Avoid use of unnecessary antibiotics
APPENDIX A

The Bristol Stool Form Scale

![Bristol Stool Form Scale Image]

APPENDIX B: Supportive Care Considerations

- Supportive care with hydration, avoidance of anti-motility agents, opiates and bile salts binding agents.
- Probiotics are not recommended in cancer patients with CDI. There are no randomized, peer reviewed studies to support the use of probiotics for the prevention or treatment of CDI in cancer patients. Cases of bacteremia (Lactobacillus) and fungemia (Saccharomyces) have been described in immunosuppressed patients receiving probiotics.
- For patients with a high index of suspicion for severe CDI and negative diagnostic studies, and if not contraindicated, consider diagnostic colonoscopy to examine for pseudomembrane formation.
- The decision for therapy in these patients is left at the discretion of the treating physician, consider Infectious Diseases consultation.

APPENDIX C: Institutional Bezlotoxumab Use Criteria (Adults Only)

- Restricted to outpatient use only, with an exception for inpatients with an extended hospitalization that would not allow outpatient administration during concomitant antibacterial treatment for C. difficile infection (anti-CDI therapy)
- Must have a positive stool C. difficile nucleic acid amplification test AND a positive toxin by enzyme-linked immunosorbent assay (ELISA)
- Must be receiving concomitant anti-CDI therapy (e.g., vancomycin, fidaxomicin, metronidazole)
- Presence of at least one of the following risk factors for recurrent CDI:
  - Age greater than or equal to 60 years
  - At least one prior episode of CDI
  - Compromised immunity; currently receiving immunosuppressants, neutropenia (i.e., ANC less than 0.5 K/microliter), and/or lymphopenia (i.e., ALC less than 0.2 K/microliter)
  - Clinically severe CDI (i.e., Zar score greater than 2)
  - Patient expected to continue non-CDI antibiotics greater than or equal to 3 days beyond end of anti-CDI therapy
APPENDIX D: Fecal Microbiota Transplant Indications

- Recurrent or relapsing CDI (all CDI must be diagnosed by positive stool test for C. difficile):
  - Three or more episodes of mild-to-moderate CDI and failures of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, or fidaxomicin).
  - At least two episodes of CDI resulting in hospitalization and associated with significant morbidity.
- CDI not responding to standard therapy (vancomycin or fidaxomicin) for at least a week.
- Severe (even fulminant CDI) with no response to standard therapy after 48 hours.

APPENDIX E: Prevention Considerations

- Prolonged courses of perioperative antibiotic prophylaxis beyond a single dose is discouraged except in selected circumstances.
- The use of prophylactic antibiotics in patients receiving chemotherapy is discouraged. Exceptions are in patients with neutropenia associated with leukemia and HSCT.
- Continued use of antibiotics during therapy for C. difficile increases risk of failure and recurrence. Discontinue concomitant antibiotics as soon as possible following diagnosis of C. difficile.
- Empiric therapy while awaiting diagnostic testing results is discouraged except in cases of suspected severe CDI (e.g., toxic megacolon, ileus, severe colitis) or when a pseudo membrane is identified on endoscopy.
- Given the high rates of asymptomatic colonization (3-8%), the detection of C. difficile nucleic acid test (NAT) by itself is not sufficient to justify specific therapy unless there is a high index of clinical suspicion (e.g., clinically significant diarrhea and no confirmed alternative causes).
  - Routine testing for C. difficile infection in children under 2 years of age with diarrhea not recommended.
- Follow infection control measures including:
  - Initiate contact isolation for suspected CDI while awaiting test results.
  - Wash hands with soap and water prior to entering and exiting the room. Wear a gown and gloves. The use of hand sanitizer is insufficient to kill C. difficile spores.
  - Clean shared patient care items with a hospital approved bleach product, according to manufacturer’s instructions.
  - Do not re-test for CDI for the sole purpose of removing isolation. Patients who are no longer passing unformed stools will be re-evaluated by an infection preventionist prior to discontinuation of isolation. Only an infection preventionist has the authority to remove patients from isolation.
- Preferably delay chemotherapy until CDI treatment has been completed and diarrhea has resolved.
- Consider delaying radiation therapy until GI symptoms have resolved.

HSCT = hematopoietic stem cell transplant
Assessment and Management of Clostridioides difficile Infections (CDI)

SUGGESTED READINGS


Continued on next page

Department of Clinical Effectiveness V3
Approved by the Executive Committee of the Medical Staff on 09/17/2019
Assessment and Management of Clostridioides difficile Infections (CDI)

SUGGESTED READINGS - continued


Continued on next page
SUGGESTED READINGS - continued


UTMDACC Institutional Policy #CLN0432 - Isolation Policy


Assessment and Management of 
_Clostridioides difficile_ Infections (CDI)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.

DEVELOPMENT CREDITS

This practice consensus statement algorithm is based on majority opinion of the Infection Control Infectious Disease, and Pediatrics experts at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

- Samuel Aitken, PharmD (Pharmacy Clinical Programs)
- Sherry Cantu, MPH, CIC (Infection Control)†
- Jose Cortes, MD (Pediatrics)
- Farnaz Foolad, PharmD (Pharmacy Clinical Programs)
- Natalie Dailey Garnes, MD (Infectious Diseases - Pediatrics)†
- Suzanne Gettys, PharmD (Pharmacy Clinical Programs)
- Linda Graviss, MT, ASCP, CIC (Infection Control)
- Pablo Okhuysen, MD (Infectious Diseases)†
- Amy Pai, PharmD* 
- Christina Perez*
- Yinghong Wang, MD (Gastroenterology Hepatology & Nutrition)

† Core Development Team
* Clinical Effectiveness Development Team